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Abstract
Background: Cadmium (Cd) and lead (Pb) are hypothesised to be risk factors for non-Hodgkin’s lymphoma (NHL), a
group of haematological malignancies with a suspected environmental aetiology. Within the EnviroGenoMarkers
study we utilised pre-diagnostic erythrocyte concentrations of Cd and Pb to determine whether exposure was
associated with risk of B-cell NHL and multiple myeloma.
Methods: 194 incident cases of B-cell NHL and 76 cases of multiple myeloma diagnosed between 1990 and 2006
were identified from two existing cohorts; EPIC-Italy and the Northern Sweden Health and Disease Study. Cases
were matched to healthy controls by centre, age, gender and date of blood collection. Cd and Pb were measured in
blood samples provided at recruitment using inductively coupled plasma-mass spectrometry. Logistic regression was
applied to assess the association with risk. Analyses were stratified by cohort and gender and by subtype where
possible.
Results: There was little evidence of an increased risk of B-cell NHL or multiple myeloma with exposure to Cd (B-cell
NHL: OR 1.09 95%CI 0.61, 1.93, MM: OR 1.16 95% CI: 0.40, 3.40 ) or Pb (B-cell NHL: 0.93 95% CI 0.43, 2.02,
multiple myeloma: OR 1.63 95%CI 0.45, 5.94) in the total population when comparing the highest to the lowest
quartile of exposure. However, gender and cohort specific differences in results were observed. In females the risk of
B-cell NHL was more than doubled in those with a body burden of Cd >1µg/L (OR 2.20 95%CI; 1.04, 4.65).
Conclusions: This nested case-control study does not support a consistent positive association between Cd or Pb
and NHL, but there is some indication of a gender specific effect suggesting further research is warranted.
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Introduction
Non-essential metals such as cadmium (Cd) and lead (Pb)
are ubiquitous persistent environmental toxicants known to
bioaccumulate in the human body. Both metals are highly toxic
even in trace amounts [1], and the global burden of Cd and Pb
remains high due to their widespread usage in industrial and
manufacturing processes and through contaminated phosphate
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fertilisers [2–4]. Exposure occurs primarily through the
ingestion of contaminated food and drinking water, the
inhalation of contaminated air, and smoking [1,5,6].
Consequently, Pb and Cd constitute some of the most
widespread environmental pollutants in the world and, with no
known beneficial physiological role [1,7] they represent an
important public health burden [5,6].
Since 1993, Cd and its compounds have been classified as
group 1 carcinogens by the International Agency for Research
on Cancer (IARC), based on sufficient evidence from animal
models and increased incidence of breast and lung cancer in
humans [8]. Pb is classified as a possible human carcinogen
(group2b), while its inorganic compounds are deemed probable
carcinogens (group 2a) [9] based on limited epidemiological
evidence for an increased risk of lung, stomach, kidney and
brain cancers [2]. Multiple molecular and cellular mechanisms
are thought to contribute both to the carcinogenicity of Cd and
to the suspected carcinogenicity of Pb in humans [10,11].
Non-Hodgkin’s lymphomas (NHL) are a heterogeneous
group of lymphoid malignancies whose aetiology is largely
unknown. The best characterised risk factor to date is severe
immunodeficiency [12]. However, this accounts for only a small
percentage of cases and evidence from epidemiological and
occupational studies suggests an environmental aetiology. In
particular, polychlorinated biphenyls (PCBs) and dioxins have
been implicated in studies of occupationally exposed cohorts or
populations living in the vicinity of industrial sources of these
pollutants. This association is supported by the temporal
relationship between worldwide usage and incidence trends of
NHL [13]. Similarly, there is evidence for an increase of NHL
incidence in populations living near refineries that emit Pb and
Cd [14]. Both agents have been observed to modulate the
immune system [3,15,16] and furthermore, a primary target of
Pb [17] and a secondary target of Cd is the hematopoietic
system [17,18], making these metals plausible candidate risk
factors for NHL.
The EnviroGenoMarkers Study is a case-control study
nested within two prospective cohorts aiming at the
development of a new generation of biomarkers to better
characterise the relationship between exposure to
environmental pollutants and adverse health effects. The aim
of the present study was to analyse the relationship between
pre-diagnostic blood erythrocyte concentrations of Pb and Cd
and risk of B-cell NHL and multiple myeloma.
Materials and Methods
Ethics Statement
This study was approved by the committees on research
ethics in Umea (Dnr 08-215M) and in Florence (ref 347/2009)
in accordance with the Declaration of Helsinki of the World
Medical Association. All participants provided written consent
at recruitment.
Study subjects
The EnviroGenoMarkers study is based on participants from
two existing prospective cohort studies: EPIC-Italy [19] and the
Northern Sweden Health and Disease Study (NSHDS) [20]. In
both, blood samples were prospectively collected from healthy
subjects at enrolment.
EPIC-Italy is a subset of the European prospective
Investigation into Cancer and nutrition. Overall, 47,749
volunteers aged 35-70 years were enrolled in five participating
centres across Italy; Varese, Florence, Turin, Naples and
Ragusa, between 1993 and 1998. At enrolment, all participants
signed an informed consent form agreeing to provide detailed
information on their dietary and life-style habits at recruitment
and to have their health status followed for the rest of their
lives. Standardized procedures were used to identify newly
diagnosed cases of cancer based on automated linkages to
cancer and mortality registries, municipal population offices
and hospital discharge systems. In Naples follow up
information was collected through periodic personal contact.
The NSHDS includes participants from the Västerbotten
Intervention program, the Västerbotten Mammary Screening
Program and the Northern Sweden MONICA project. A total of
95,000 healthy individuals aged 40-60 were invited for inclusion
in the project between 1990 and 2006. At initial recruitment,
subjects were asked to complete a self- administered
questionnaire to collect demographic, medical and lifestyle
information and a separate self-administered food frequency
questionnaire. Informed consent was obtained from all
participants and a medical examination was conducted during
which a blood sample was taken. Invasive cancers occurring
among cohort members during the study period were identiﬁed
by linkage with the Swedish Cancer Registry and the local
Northern Sweden Cancer Registry.
Lymphoma cases that occurred within the two cohorts
between 2 and 16 years of follow up were identified.
Lymphoma cases were classified into subtypes according to
the SEER ICD-0-3 morphology codes [21]. All eligible B-cell
NHL cases, including multiple myeloma were included. For
each case one suitable cancer-free control was selected by
incidence matching from the remaining populations matched on
gender, age (+/- 2.5 years), centre and date of blood collection
(+/- 6 months). More than 95% of participants also had the
same fasting status as their matched pair at blood extraction.
Information from the two studies was integrated into a single
database and calibrated.
Exposure Assessment
Exposure to metals was assessed by measurements in
stored erythrocytes. Blood samples were collected in citrate
(Italy) or heparin (Sweden) tubes and processed by
centrifugation on the same day of collection (Italy) and within
one hour of collection (Sweden). Aliquots (0.5ml) were stored
in liquid nitrogen tanks at -196°C in Italy and -80°C in Sweden.
The concentrations of Cd and Pb in erythrocytes were
determined by inductively coupled plasma-mass spectrometry
(ICP-MS; Thermo X7, Thermo Elemental, Winsford, UK) in
samples diluted with an alkaline solution according to Barany et
al [22]. The detection limit, calculated as 3 times the standard
deviation (SD) of the blank was 0.03 and 0.09 µg/L for Cd and
Pb respectively. The analytical accuracy was checked against
human blood reference material from Centre de Toxicologie du
Quebec, International Comparison Program, Canada. The
Cadmium, Lead and the Risk of Non-Hodgkin Lymphoma
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results (mean ± SD) obtained were for Cd (Lot. C0616 and
C0912) 0.98 ± 0.04 and 5.0 ± 0.18 µg/L (n = 69) vs.
recommended 1.0 ± 0.13 and 5.3 ± 0.43 µg/L, respectively and
for Pb (Lot. L0909 and L0807) 23 ± 0.043 and 112 ± 3.9 µg/L
(n = 69) vs. recommended 23 ± 1.1 and 112 ± 9.9 µg/L,
respectively. All samples were prepared in duplicate and the
method imprecision (calculated as the coefficient of variation
for duplicate preparation measurements) was 5 and 3% for Cd
and Pb respectively.
To reduce the impact of technically-induced variation,
matched pairs were analysed in the same batch on the same
day. As matching was performed by sample date each case
therefore had the same storage time as its matched control.
Statistical analysis
We conducted all analyses on the total population as well as
by cohort and gender where appropriate. To take potential
subtype heterogeneity into account, subtype specific analyses
were conducted to the most detailed extent allowable by
sample size, according to the hierarchies proposed by Morton
et al [23]. The statistical significance of the differences in
baseline characteristics between cases and controls were
determined using the Student’s t-test and the chi-squared test
for continuous and categorical outcomes respectively. Due to
typically non-Gaussian distributions of erythrocyte
concentrations for the two metals, these were explored by non-
parametric methods. Namely cohort and gender specific
analyses used ranksum test and the case-control status
analyses used the Wilcoxon signed rank test.
Cases were categorised into ordered quartiles based on the
distribution of Cd or Pb in the matched control population and a
further binary variable was created to assess whether blood
concentration exceeded levels previously identified in the
literature as ‘toxic’ or ‘harmful’: >1 µg/L [7] and >100 µg/L [1]
for Cd and Pb respectively. Conditional logistic regression
analyses were utilised to calculate odds ratios and 95%
confidence intervals accounting for the matching factors.
Unconditional logistic regression using log transformed
exposure levels as a continuous variable and adjusting for the
matching variables was used to consider subtype
heterogeneity and the effect of time between blood draw and
diagnosis. All controls were included in these analyses to
maximise power. The Mantel-Haenszel score test was then
used to check for significant heterogeneity between the odds
ratios for the four largest subtypes and between those
diagnosed within five years of blood draw compared to those
diagnosed more than five years after blood draw. Confounding
was assessed by including additional lifestyle variables (see
Table S1 in File S1) in the models and applying the likelihood
ratio test to assess the relative quality of fit.
All analyses were performed using STATA 11.3 (Stata
Corporation, College Station, TX).The level of statistical
significance was set at 0.05 and all tests are two tailed.
Results
A total of 270 incident cases were identified during follow-up;
84 from EPIC Italy and 186 from NSHDS, including 76 cases of
multiple myeloma (see Figure S1 in File S1). There were no
significant differences between cases and controls for any of
the baseline variables investigated (Table 1).
Concentrations in all blood samples were above the limit of
quantification for both metals. When the total population (cases
and controls combined) was considered females had a higher
body burden of Cd than males (median [range]: 0.61 μg/L
[0.10, 4.32] and 0.37 μg/L [0.10, 5.22], for females and males
respectively, p=0.006), while Pb was higher in males; 61.85
μg/L [15.42, 672.48] compared to females; 52.71 μg/L [11.20,
400.84] p<0.001). The median concentrations of both metals
were significantly (p<0.001) higher in the Italian cohort (Cd:
0.61μg/L [0.10, 3.58] vs. 0.41μg/L [0.10, 5.22] in Sweden. Pb:
Table 1. Baseline characteristics of cases and controls.
Baseline variable Case (n=270)   
Control
(n=270)   Difference
  [n (%)] [n (%)] (p-value)*
Cohort EPIC-Italy 84 (31.1) 84 (31.1)  
 NSHDS 186 (68.9) 186 (68.9)  
Gender Male 133 (49.3) 133 (49.3)  
 Female 137 (50.7) 137 (50.7)  
Mean Age (yrs) 53.08 53.09 0.989
Mean Height (cm) 169.55 168.24 0.120
Mean Weight (kg) 76.48 75.09 0.267
BMI Underweight 1 (0.4) 0 (0.0)  
 Normal 104 (38.5) 109 (40.4)  
 Overweight 121 (44.8) 118 (43.7)  
 Obese 40 (14.8) 39 (14.4)  
 unknown 4 (1.5) 4 (1.5) 0.883
Smoking status Never 121 (44.8) 134 (49.6)  
 Former 90 (33.3) 72 (26.7)  
 Current 57 (21.1) 54 (20.0)  
 unknown 2 (0.7) 10 (3.7) 0.269
Highest
educational
level
None 4 (1.5) 1 (0.4)  
 Primary 94 (34.8) 98 (36.3)  
 Technical/professional 68 (25.2) 54 (20.0)  
 Secondary 52 (19.3) 64 (23.7)  
 University/college 47 (17.4) 42 (15.6)  
 unknown 5 (1.9) 11 (4.1) 0.202
Cambridge
physical
activity index
Inactive 80 (29.6) 75 (27.8)  
 Moderatelyinactive 106 (39.3) 95 (35.2)  
 Moderatelyactive 69 (25.6) 76 (28.2)  
 Active 14 (5.2) 23 (8.5)  
 unknown 1 (0.4) 1 (0.4) 0.510
* P-value for difference was calculated using the chi-squared test for categorical
baseline variables and the student’s t-test for continuous variables
doi: 10.1371/journal.pone.0081892.t001
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91.91μg/L [39.29, 400.84] vs. 44.99μg/L [11.20, 672.48] in
Sweden). There was a weak positive correlation between
erythrocyte concentrations of Cd and Pb (r2=0.190, p<0.001),
which was evident in both cohorts.
There was no significant difference in median or mean
erythrocyte concentrations between cases and controls for
either metal (tables S2 and S3 in File S1). There was also no
difference when the results were stratified by cohort or gender,
Tables 2 and 3 describe the risk estimates when exposure
levels were categorised into quartiles based on the control
population, again no significant increases were observed. In
the full population the risk of B-cell NHL in the highest
compared to the lowest quartile of exposure was OR 0.93 (95%
CI: 0.43, 2.02) and OR 1.09 (95% CI: 0.61, 1.93) for Pb and
Cd, respectively. While for multiple myeloma the odds ratios
were OR 1.63 (95% CI: 0.45, 5.94) for Pb and OR 1.16 (95%
CI: 0.40, 3.40) for Cd.
Information on histological subtype was available for 225 of
270 cases (83%) and the remaining 45 cases were classified
as ‘B-cell lymphoma not otherwise specified’. There was little
evidence of an increased risk associated with metal exposure
for any of the four largest subtype groups; multiple myeloma,
diffuse large B-cell lymphoma, B-cell chronic lymphatic
leukaemia, or follicular lymphoma, although there was a
consistent non-significant increase in risk in females across all
subtypes(Tables 4 and 5 for Pb and Cd respectively). Despite
apparent heterogeneous estimates of odds ratios across the
subtypes (in every population of interest), Mantel-Haenszel
score did reveal any significant differences results (p>0.3).
The number and percentage of cases and controls above the
toxic or harmful concentration level for Pb and Cd are shown in
tables 6 and 7 respectively. There was no significantly
increased risk of B-cell NHL or of multiple myeloma associated
with being above 100µg/L for Pb. (Table 6). .Females above
1µg/L for Cd had more than double the risk of B-cell NHL
compared to those in the lowest quartile of exposure (OR 2.20
95%CI; 1.04, 4.65) (Table 7). An increased risk was also
observed for multiple myeloma, although it was not significant
(OR; 1.43 95%CI 0.54, 3.75).
The median time from blood collection to diagnosis was 6.6
years in NSHDS and 5.0 in Epic-Italy (table S4 in File S1).
There was no association between time from blood draw to
NHL diagnosis and erythrocyte concentrations of Cd (p=0.555)
or Pb (p=0.549) in the cases. Although there did appear to be
some differences between cases with ≥ 5 years between blood
draw and diagnosis compared to those with ≤ 5 years, in
certain subpopulations (table S5 in File S1) there was no
significant heterogeneity in the odds ratios (Mantel-Haenzsel
score test p<0.5 for all subpopulations).
Adjustment of these models for potential confounders did not
alter any of the findings (results not shown).
Discussion
Pb and Cd are two of the most widespread environmental
and industrial toxins globally [10] and they have both been
associated with a range of medical conditions
[2,4,24,25] .Whilst Cd is a known human carcinogen, the
evidence for Pb is less compelling. We conducted a
prospective study to determine whether these two metals were
associated with an increased risk of NHL, which represents the
first such study in this field. Our results indicate an association
between B-cell NHL and Cd in females, particularly at the
relatively high exposure levels defined as toxic or harmful in
this study. However no such relationship was evident in males.
Similarly we did not observe an association between
prediagnostic levels of Pb and risk of NHL in either gender.
Cohort and gender-specific differences were evident
throughout the study; Cd was found to be at higher
concentrations in females and in the Italian cohorts, and it was
in these subgroups that the strongest associations with B-cell
NHL were observed. There was additionally some evidence
that risk may differ by subtype, however, the subtype analyses
were limited by the small number of observations. Additional
analysis not presented in the manuscript did not provide any
evidence for confounding in the relationship between either
metal and B-cell NHL.
Metals may induce carcinogenesis through a number of
mechanisms. In vitro studies indicate that both Cd and Pb have
genotoxic properties [10,11] and there is evidence that both
metals can induce DNA damage via elevated levels of
oxidative stress [1]. However, although the evidence from
animal models is strong, epidemiological evidence in humans,
particularly for Pb, is less consistent and lacks a clear dose–
response relationship [11,26]. Studies in humans have mainly
been based on small, male, occupationally exposed
populations and tend to lack sufficient information on historical
exposure [7,26]. Furthermore the strongest epidemiological
evidence for Pb comes from studies of population living near to
oil refineries, which also emit other suspected haematological
carcinogens such as benzene and dioxins [14,27].
In our study of a general, non-occupationally exposed cohort,
exposure was assessed using erythrocyte concentrations of Pb
and Cd in blood samples taken from cancer-free individuals at
recruitment to the cohort. This provides a point estimate of
historical exposure free from recall bias. Although urine is
considered to be the best biomaterial to measure biomarkers of
lifetime Cd exposure, blood Cd has been found to correlate
highly with Cd concentrations in both urines and tissues and as
such can be considered as a good estimate of body burden [6].
Pb binds to erythrocytes and therefore body burden is optimally
assessed by blood concentration [24]. Exposure levels for both
metals were within the range of those reported in studies of
similar populations [25,28,29]. Our finding of higher levels in
females is consistent with previous studies [30] and is thought
to be related to the low iron stores common in women of fertile
age [29]. Similarly we observed higher Pb levels in males as
expected [30].
Despite evidence from animal studies we could find only one
previous study which directly explored the association between
Cd and NHL in humans; Adams et al [31] reported an
association between urinary Cd and NHL in males and an
association with leukaemia in both males and females, a
finding consistent with a case control study in a Turkish
population [17,31]. To the best of our knowledge, our study is
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the first to report on the risk of any haematological malignancy
and Pb exposure using measures of body burden.
The biological rationale for the risk effects of Cd and Pb is
based partly on their interaction with the immune system. Cd
may act through mechanisms related to the increase of
inflammatory cytokines [15,32]. While Pb has been reported to
decrease the absolute number and percentage of CD8+ and
CD4+ cells [3,6,33]; such a decrease has been previously
associated with well characterised NHL risk factors including
Trichloroethylene and Carbofuran exposure [34–37].
Interestingly Pb exposure has also been associated with Ig-E
mediated type1 hypersensitivity in some studies and it has
been suggested it may contribute to an increase in allergic
conditions [16]. Atopy and allergy have been reported to
reduce the risk of NHL [12] and therefore this may be affecting
our results.
Metal-induced carcinogenesis is dependent on the route,
level, and duration of exposure which is subject to individual
variation. However, even when exposed at the same levels,
host factors such as medical history, smoking habits and
simultaneous exposure to other toxic agents may play an
important role in determining the individual burden of both
metals [2]. Notably a number of studies have reported on
genetic polymorphisms which influence the metabolism and
storage of these metals and which may affect our results.
Large individual variation in the expression of Metallothionein,
a protein which binds the majority of Cd in the body [1] and
polymorphisms in SLC4A7 and ALAD, which affect Pb influx
and the binding of Pb in erythrocytes [38,39], have been
identified as candidates for the variation in concentrations of
these metals between individuals.
The gender differences observed in our findings are of
particular note, given the recent interest in gender-specific
susceptibility to carcinogens [40]. A growing body of
mechanistic, experimental and epidemiological evidence
suggests that women may be more susceptible to the effect of
carcinogens than males [41]. This relates both to baseline
differences in exposure levels to putative carcinogens as well
hormonal, physiological, genetic and epigenetic effects[42].
Gender-differences in the expression of xenobiotic
metabolising enzymes including the cytochrome P450 system
and the human glutathione S-transferases [41,42], and in
candidate transporter genes for carcinogen export have been
reported[40]. While a number of studies have observed greater
levels of markers of DNA damage including DNA adduct levels,
sister chromatid exchanges (SCEs) and micronucleus
frequency in female cancer patients compared to similarly
exposed male cases [40,42]. DNA repair capacity has also
been reported to be substantially lower in females, while
expression of the oncogenic k-ras mutation has been found to
be higher. It is thought that these effects may be regulated by
hormonal responses and that estrogen in particular may play
an important role [40–42].
Table 4. Association between prediagnostic exposure levels of Pb and risk of NHL by subtype.
Subtype  Population Cases Controlsa   
  n median (µg/L) n median (µg/L) ORb (95% CI) P-value
Multiple Myeloma Total 76 55.338 269 57.597 1.04 (0.57, 1.90) 0.888
 Sweden 55 44.674 185 45.464 1.23 (0.64, 2.37) 0.538
 Italy 21 92.373 84 89.594 0.33 (0.07, 1.59) 0.168
 Men 34 66.320 132 60.926 0.83 (0.35, 1.96) 0.676
 Women 42 47.958 137 53.407 1.28 (0.53, 3.08) 0.587
Diffuse Large B-cell Lymphoma Total 45 53.467 269 57.597 0.60 (0.26, 1.40) 0.239
 Sweden 34 48.576 185 45.464 0.70 (0.28, 1.73) 0.433
 Italy 11 100.328 84 89.594 0.38 (0.03, 5.04) 0.459
 Men 24 61.473 132 60.926 0.97 (0.35, 2.64) 0.949
 Women 21 53.294 137 53.407 0.29 (0.07, 1.18) 0.085
B-cell Chronic Lymphatic Lymphoma Total 42 51.392 269 57.597 0.71 (0.32, 1.57) 0.392
 Sweden 31 40.927 185 45.464 1.00 (0.43, 2.33) 0.996
 Italy 11 65.845 84 89.594 0.12 (0.02, 0.87) 0.036*
 Men 25 55.933 132 60.926 0.63 (0.23, 1.74) 0.376
 Women 17 44.373 137 53.407 0.79 (0.17, 3.60) 0.764
Follicular Lymphoma Total 39 66.968 269 57.597 1.17 (0.52, 2.63) 0.701
 Sweden 19 44.157 185 45.464 1.19 (0.43, 3.29) 0.738
 Italy 20 90.278 84 89.594 1.14 (0.30, 4.31) 0.850
 Men 19 78.363 132 60.926 0.80 (0.25, 2.55) 0.706
 Women 20 66.479 137 53.407 1.91 (0.54, 6.78) 0.317
a For each subpopulation (Sweden, Italy, Males, Females) all controls were used, regardless of case subtype, in order to maximise power
b Risk of NHL associated with a one unit increase in log transformed exposure levels. Computed using unconditional logistic regression adjusting for sex, age, centre, batch
and sample date
* p<0.05
doi: 10.1371/journal.pone.0081892.t004
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Table 5. Association between prediagnostic exposure
levels of Cd and risk of NHL by subtype.
Subtype  Population   Cases Controlsa   
  n
median
(µg/L) n
median
(µg/L)
ORb (95%
CI)   P-value
Multiple
Myeloma Total 76 0.531 269 0.498
1.07 (0.77,
1.49) 0.683
 Sweden 55 0.383 185 0.410 0.92 (0.63,1.34) 0.664
 Italy 21 0.603 84 0.589 2.34 (0.89,6.12) 0.084
 Men 34 0.346 132 0.384 0.73 (0.43,1.24) 0.248
 Women 42 0.662 137 0.543 1.51 (0.92,2.46) 0.102
Diffuse Large
B-cell
Lymphoma
Total 45 0.539 269 0.498 0.95 (0.61,1.48) 0.804
 Sweden 34 0.435 185 0.410 0.92 (0.57,1.49) 0.730
 Italy 11 0.633 84 0.589 1.50 (0.42,5.33) 0.529
 Men 24 0.362 132 0.384 0.91 (0.51,1.63) 0.755
 Women 21 0.638 137 0.543 1.13 (0.53,2.39) 0.754
B-cell
Chronic
Lymphatic
Lymphoma
Total 42 0.398 269 0.498 0.82 (0.52,1.30) 0.400
 Sweden 31 0.370 185 0.410 0.74 (0.43,1.25) 0.256
 Italy 11 0.904 84 0.589 1.04 (0.34,3.18) 0.950
 Men 25 0.299 132 0.384 0.45 (0.21,0.97) 0.040
*
 Women 17 0.618 137 0.543 1.48 (0.73,3.00) 0.271
Follicular
Lymphoma Total 39 0.598 269 0.498
1.48 (0.94,
2.32) 0.088
 Sweden 19 0.568 185 0.410 1.27 (0.74,2.20) 0.389
 Italy 20 0.606 84 0.589 2.83 (1.11,7.20) 0.029
*
 Men 19 0.538 132 0.384 1.52 (0.87,2.67) 0.141
 Women 20 0.599 137 0.543 1.51 (0.70,3.25) 0.293
a For each subpopulation (Sweden, Italy, Males, Females) all controls were used,
regardless of case subtype, in order to maximise power
b Risk of NHL associated with a one unit increased in log transformed exposure
levels. Computed using unconditional logistic regression adjusting for sex, age,
centre, batch and sample date
* p<0.05
doi: 10.1371/journal.pone.0081892.t005
Alternatively our findings may simply reflect the lower
baseline risk of NHL in unexposed women[40]; NHL is 50%
Table 6. Number (%) of cases and controls above toxic
levels of Pb (>100µg/L) and association with NHL.
Subtype Population   
Cases n.
(%)   
Controls n.
(%) ORa (95% CI)   P-value
B-cell NHL Total 37 (19.1) 35 (18.0) 1.10 (0.60, 2.02) 0.758
 Sweden 10 (7.6) 8 (6.1) 1.29 (0.48, 3.45) 0.618
 Italy 27 (42.9) 27 (42.9) 1.00 (0.46, 2.16) 1.000
 Men 24 (24.2) 25 (25.3) 0.93 (0.44, 1.98) 0.847
 Women 13 (13.7) 10 (10.5) 1.50 (0.53, 4.21) 0.442
Multiple
myeloma Total 13 (17.1) 11 (14.5) 1.29 (0.48, 3.45) 0.618
 Sweden 5 (9.1) 2 (3.6) 2.50 (0.49,12.89) 0.273
 Italy 8 (38.1) 9 (42.9) 0.80 (0.21, 2.98) 0.739
 Men 7 (20.6) 8 (23.5) 0.80 (0.21, 2.98) 0.739
 Women 6 (14.3) 3 (7.1) 2.50 (0.49, 12.89) 0.273
a Risk of NHL in those above the toxic level of exposure compared to the risk of
NHL in those below the toxic level of exposure. Computed using conditional logistic
regression
* p<0.05
doi: 10.1371/journal.pone.0081892.t006
Table 7. Number (%) of cases and controls above toxic
levels of Cd (>1µg/L) and association with NHL.
Subtype Population   
Cases n.
(%)   
Controls n.
(%) ORa (95% CI) P-value
B-cell NHL Total 39 (20.1) 30 (15.5) 1.39 (0.81,2.38) 0.227
 Sweden 24 (18.3) 22 (16.8) 1.11 (0.59,2.10) 0.746
 Italy 15 (23.8) 8 (12.7) 2.40 (0.85,6.81) 0.100
 Men 14 (14.1) 17 (17.2) 0.77 (0.34,1.75) 0.533
 Women 25 (26.3) 13 (13.7) 2.20 (1.04,4.65) 0.039
*
Multiple
myeloma Total 19 (25.0) 18 (23.7)
1.09 (0.48,
2.47) 0.835
 Sweden 12 (21.8) 13 (23.6) 0.88 (0.32,2.41) 0.796
 Italy 7 (33.3) 5 (23.8) 1.67 (0.40,6.97) 0.484
 Men 4 (11.8) 6 (17.6) 0.50 (0.09,2.73) 0.423
 Women 15 (35.7) 12 (28.6) 1.43 (0.54,3.75) 0.469
a Risk of NHL in those above the toxic level of exposure compared to the risk of
NHL in those below the toxic level of exposure. Computed using conditional logistic
regression
* p<0.05
doi: 10.1371/journal.pone.0081892.t007
Cadmium, Lead and the Risk of Non-Hodgkin Lymphoma
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e81892
more common among men [43]. However, other Cd-associated
health effects have previously been observed to be more
common in women than men [30] and we believe our results
indicate the need for further gender-specific studies.
Subtype-specific analyses, to the most detailed extent
possible within the constraints of our sample size, were
conducted in addition to the analysis of the total population.
Although also a B-cell derived malignancy, due to its
pathophysiological differences to the other subtypes multiple
myeloma has been evaluated separately in this manuscript. We
observed no significant heterogeneity between subtypes.
Aetiology is largely unknown for most B-cell NHL subtypes and
although there is evidence that some risk factors are subtype
specific, others such as benzene [44], have been found to
contribute to multiple subtypes. It is of note that, in this study
our only significant finding; that of an increased risk with Cd
exposure in females, was evident, although non-significant,
across all subtypes including multiple myeloma. The lack of
significance in the subtype-specific analyses may simply reflect
the small sample size.
Previous studies of NHL and environmental exposures have
noted an effect of ‘time to diagnosis’ i.e. the time between
sample collection and diagnosis date; with stronger
associations observed closer to diagnosis [45–47]. This is
thought to be due to the pathophysiologic changes such as
lipid mobilization, weight loss, and metabolic changes,
accompanying carcinogenesis which may affect the body
burden of exposures [48]. To ensure that pre-diagnostic
subclinical changes in cases who were diagnosed shortly after
blood draw were not modifying the body burden of exogenous
exposures [48] we stratified on the time between blood draw
and diagnosis. The association with Cd was fairly consistent
across strata although there was some indication that the
findings in subset analyses of women may have been driven by
the individuals with <5 years from sampling to diagnosis, based
on the larger effect size in this group.Conversely, the results
suggested a more strongly inverse association with Pb in those
who were diagnosed less than five years after blood draw,
which may be the result of lowered Pb concentrations due to
subclinical cancer. However these analyses were limited by
small numbers and deserve replication in a larger cohort with
sufficient power.
There were a number of strengths of this study; our
prospective study design protected against selection bias and
the problem of reverse causation. Our case and control
populations were similar with respect to baseline factors and
additional confounders. Finally we attempted to exclude from
some analyses participants whose body burden of metals may
have been influenced by pre-cancerous changes. Conversely
our study lacked information on family history of NHL and on
grade or staging of the tumours. Additionally, we were not able
to control for other unmeasured metals and trace elements
which may be exerting interaction effects on the risk of NHL.
We only have a one spot measurement so our exposure
estimate is based on a single time period that is not necessarily
representative of lifetime exposure.
Conclusions
In conclusion in this nested case control study we do not find
a consistent association with prediagnostic erythrocyte
concentrations of Cd or Pb and risk of NHL, although there is
some indication that high exposure to Cd may increase risk in
females only. Our results were robust to adjustment and do not
seem to be the result of confounding, although we did not
correct for multiple testing and cannot rule out the possibility of
false positives. Our findings may suggest that the carcinogenic
potential of Cd is only realised at high concentrations and
therefore levels in males may have been too low to show a
clinical effect. This could also explain the differing results by
cohort: Italy, in which levels of Cd were higher than in Sweden,
showed the greatest risk. However gender-specific
susceptibility to carcinogens is also likely to play a role. We
report an essentially null association between B-cell NHL risk
and prediagnostic concentrations of Pb.
These results are among the first in the field of metal
exposure and NHL aetiology and although there is little to
suggest that Cd or Pb constitute major risk factors for NHL, Cd
exposure in females in particular is worthy of further
investigation. Our findings underline the need for a larger
sample size and the importance of gender-specific analyses in
any such future studies.
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